Horm Metab Res 2022; 54(11): 715-720
DOI: 10.1055/a-1945-9694
Review

Post COVID and Apheresis – Where are we Standing?

Charlotte Steenblock 
1   Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Romy Walther
1   Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Sergey Tselmin
1   Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Natalia Jarzebska
1   Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
2   University Center for Vascular Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Karin Voit-Bak
3   Zentrum für Apherese- und Hämofiltration am INUS Tagesklinikum, Cham, Germany
,
Nicole Toepfner
4   Department of Pediatrics, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Timo Siepmann
5   Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Jens Passauer
1   Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Christian Hugo
1   Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Gloria Wintermann
6   Department of Psychotherapy and Psychosomatic Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Ulrich Julius
1   Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Mahmoud Barbir
7   Department of Cardiology, Harefield Hospital, Harefield, United Kingdom of Great Britain and Northern Ireland
,
Tina Z. Khan
7   Department of Cardiology, Harefield Hospital, Harefield, United Kingdom of Great Britain and Northern Ireland
,
Milo A. Puhan
8   Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
,
Richard Straube
1   Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Bernd Hohenstein
1   Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Stefan R. Bornstein
1   Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
9   School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences & Medicine, King’s College London, London, United Kingdom of Great Britain and Northern Ireland
,
Roman N. Rodionov
1   Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
2   University Center for Vascular Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

A continual increase in cases of Long/Post COVID constitutes a medical and socioeconomic challenge to health systems around the globe. While the true extent of this problem cannot yet be fully evaluated, recent data suggest that up to 20% of people with confirmed SARS-CoV-2 suffer from clinically relevant symptoms of Long/Post COVID several weeks to months after the acute phase. The clinical presentation is highly variable with the main symptoms being chronic fatigue, dyspnea, and cognitive symptoms. Extracorporeal apheresis has been suggested to alleviate symptoms of Post/COVID. Thus, numerous patients are currently treated with apheresis. However, at present there is no data from randomized controlled trials available to confirm the efficacy. Therefore, physicians rely on the experience of practitioners and centers performing this treatment. Here, we summarize clinical experience on extracorporeal apheresis in patients with Post/COVID from centers across Germany.

Key words

long COVID - post COVID - apheresis - fatigue - autoantibodies - Immunity


Publication History

Received: 12 August 2022

Accepted after revision: 16 September 2022

Accepted Manuscript online:
16 September 2022

Article published online:
27 October 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 National Institute for Health and Care Excellence: Clinical Guidelines. In, COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (NICE) Copyright NICE. 2020
    Google Scholar
  • 2 Huang L, Li X, Gu X. et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med 2022; 10: 863-876
    CrossrefPubMedGoogle Scholar
  • 3 Bornstein SR, Cozma D, Kamel M. et al. Long-COVID, metabolic and endocrine disease. Horm Metab Res 2022; 54: 562-566
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Choutka J, Jansari V, Hornig M. et al. Unexplained post-acute infection syndromes. Nat Med 2022; 28: 911-923
    CrossrefPubMedGoogle Scholar
  • 5 Joob B, Wiwanitkit V. Blood viscosity of COVID-19 patient: a preliminary report. Am J Blood Res 2021; 11: 93-95
    Google Scholar
  • 6 Kubánková M, Hohberger B, Hoffmanns J. et al. Physical phenotype of blood cells is altered in COVID-19. Biophys J 2021; 120: 2838-2847
    CrossrefPubMedGoogle Scholar
  • 7 Kanczkowski W, Beuschlein F, Bornstein SR. Is there a role for the adrenal glands in long COVID?. Nat Rev Endocrinol 2022; 18: 451-452
    CrossrefPubMedGoogle Scholar
  • 8 Kanczkowski W, Evert K, Stadtmuller M. et al. COVID-19 targets human adrenal glands. Lancet Diabetes Endocrinol 2022; 10: 13-16
    CrossrefPubMedGoogle Scholar
  • 9 Paul T, Ledderose S, Bartsch H. et al. Adrenal tropism of SARS-CoV-2 and adrenal findings in a post-mortem case series of patients with severe fatal COVID-19. Nat Commun 2022; 13: 1589
    CrossrefPubMedGoogle Scholar
  • 10 Bornstein SR, Voit-Bak K, Donate T. et al. Chronic post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis?. Mol Psychiatry 2022; 27: 34-37
    CrossrefPubMedGoogle Scholar
  • 11 Abbasi K. Long covid and apheresis: a miracle cure sold on a hypothesis of hope. BMJ 2022; 378: o1733
    CrossrefPubMedGoogle Scholar
  • 12 Davies M. Long covid patients travel abroad for expensive and experimental “blood washing”. BMJ 2022; 378: o1671
    CrossrefPubMedGoogle Scholar
  • 13 Bechmann N, Barthel A, Schedl A. et al. Sexual dimorphism in COVID-19: potential clinical and public health implications. Lancet Diabetes Endocrinol 2022; 10: 221-230
    CrossrefPubMedGoogle Scholar
  • 14 Torjesen I. Covid-19: Middle aged women face greater risk of debilitating long term symptoms. BMJ 2021; 372: n829
    CrossrefPubMedGoogle Scholar
  • 15 Honigsbaum M. “An inexpressible dread”: psychoses of influenza at fin-de-siècle. The Lancet 2013; 381: 988-989
    CrossrefPubMedGoogle Scholar
  • 16 Stefano GB. Historical insight into infections and disorders associated with neurological and psychiatric sequelae similar to long COVID. Med Sci Monit 2021; 27: e931447
    CrossrefPubMedGoogle Scholar
  • 17 Poenaru S, Abdallah SJ, Corrales-Medina V. et al. COVID-19 and post-infectious myalgic encephalomyelitis/chronic fatigue syndrome: a narrative review. Ther Adv Infect Dis 2021; 8 20499361211009385
    PubMedGoogle Scholar
  • 18 Steenblock C, Schwarz PEH, Perakakis N. et al. The interface of COVID-19, diabetes, and depression. Discov Ment Health 2022; 2: 5
    CrossrefPubMedGoogle Scholar
  • 19 Sotzny F, Blanco J, Capelli E. et al. Myalgic encephalomyelitis/chronic fatigue syndrome – evidence for an autoimmune disease. Autoimmun Rev 2018; 17: 601-609
    CrossrefPubMedGoogle Scholar
  • 20 Berger G. Escape of pathogens from the host immune response by mutations and mimicry. Possible means to improve vaccine performance. Med Hypotheses 2015; 85: 664-669
    CrossrefPubMedGoogle Scholar
  • 21 Segal Y, Shoenfeld Y. Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction. Cell Mol Immunol 2018; 15: 586-594
    CrossrefPubMedGoogle Scholar
  • 22 Loebel M, Grabowski P, Heidecke H. et al. Antibodies to beta adrenergic and muscarinic cholinergic receptors in patients with chronic fatigue syndrome. Brain Behav Immun 2016; 52: 32-39
    CrossrefPubMedGoogle Scholar
  • 23 Danilenko OV, Gavrilova NY, Churilov LP. Chronic fatigue exhibits heterogeneous autoimmunity characteristics which reflect etiology. Pathophysiology 2022; 29: 187-199
    CrossrefPubMedGoogle Scholar
  • 24 Fluge Ø, Bruland O, Risa K. et al. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS One 2011; 6: e26358
    CrossrefPubMedGoogle Scholar
  • 25 Fluge Ø, Risa K, Lunde S. et al. B-Lymphocyte depletion in myalgic encephalopathy/chronic fatigue syndrome. An open-label phase II study with rituximab maintenance treatment. PLoS One 2015; 10: e0129898
    CrossrefPubMedGoogle Scholar
  • 26 Fluge Ø, Rekeland IG, Lien K. et al. B-Lymphocyte depletion in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2019; 170: 585-593
    CrossrefPubMedGoogle Scholar
  • 27 Angileri F, Legare S, Marino Gammazza A. et al. Molecular mimicry may explain multi-organ damage in COVID-19. Autoimmun Rev 2020; 19: 102591
    CrossrefPubMedGoogle Scholar
  • 28 Mobasheri L, Nasirpour MH, Masoumi E. et al. SARS-CoV-2 triggering autoimmune diseases. Cytokine 2022; 154: 155873
    CrossrefPubMedGoogle Scholar
  • 29 Lucchese G, Floel A. Molecular mimicry between SARS-CoV-2 and respiratory pacemaker neurons. Autoimmun Rev 2020; 19: 102556
    CrossrefPubMedGoogle Scholar
  • 30 Bastard P, Rosen LB, Zhang Q. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020; 370 eabd4585
    PubMedGoogle Scholar
  • 31 Koning R, Bastard P, Casanova JL. et al. Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intensive Care Med 2021; 47: 704-706
    CrossrefPubMedGoogle Scholar
  • 32 Troya J, Bastard P, Planas-Serra L. et al. Neutralizing autoantibodies to type I IFNs in>10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain. J Clin Immunol 2021; 41: 914-922
    CrossrefPubMedGoogle Scholar
  • 33 Byrne CJ, Khurana S, Kumar A. et al. Inflammatory signaling in hypertension: regulation of adrenal catecholamine biosynthesis. Front Endocrinol (Lausanne) 2018; 9: 343
    CrossrefPubMedGoogle Scholar
  • 34 Wallukat G, Hohberger B, Wenzel K. et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun 2021; 4: 100100
    CrossrefPubMedGoogle Scholar
  • 35 Bynke A, Julin P, Gottfries CG. et al. Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in myalgic encephalomyelitis (ME) patients - A validation study in plasma and cerebrospinal fluid from two Swedish cohorts. Brain Behav Immun Health 2020; 7: 100107
    CrossrefPubMedGoogle Scholar
  • 36 Hraiech S, Bonnardel E, Guervilly C. et al. Herpes simplex virus and cytomegalovirus reactivation among severe ARDS patients under veno-venous ECMO. Ann Intensive Care 2019; 9: 142
    CrossrefPubMedGoogle Scholar
  • 37 Imlay H, Dasgupta S, Boeckh M. et al. Risk factors for cytomegalovirus reactivation and association with outcomes in critically ill adults with sepsis: a pooled analysis of prospective studies. J Infect Dis 2021; 223: 2108-2112
    CrossrefPubMedGoogle Scholar
  • 38 Imlay H, Limaye AP. Current understanding of cytomegalovirus reactivation in critical illness. J Infect Dis 2020; 221: S94-S102
    CrossrefPubMedGoogle Scholar
  • 39 Libert N, Bigaillon C, Chargari C. et al. Epstein-Barr virus reactivation in critically ill immunocompetent patients. Biomed J 2015; 38: 70-76
    CrossrefPubMedGoogle Scholar
  • 40 Gatto I, Biagioni E, Coloretti I. et al. Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality. Intensive Care Med 2022; 48: 706-713
    CrossrefPubMedGoogle Scholar
  • 41 Meng M, Zhang S, Dong X. et al. COVID-19 associated EBV reactivation and effects of ganciclovir treatment. Immun Inflamm Dis 2022; 10: e597
    CrossrefPubMedGoogle Scholar
  • 42 Zubchenko S, Kril I, Nadizhko O. et al. Herpesvirus infections and post-COVID-19 manifestations: a pilot observational study. Rheumatol Int 2022; 42: 1523-1530
    CrossrefPubMedGoogle Scholar
  • 43 Aldhaleei WA, Alnuaimi A, Bhagavathula AS. COVID-19 Induced hepatitis B virus reactivation: a novel case from the United Arab Emirates. Cureus 2020; 12: e8645
    PubMedGoogle Scholar
  • 44 Rodríguez-Tajes S, Miralpeix A, Costa J. et al. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. J Viral Hepat 2021; 28: 89-94
    CrossrefPubMedGoogle Scholar
  • 45 Shariq M, Sheikh JA, Quadir N. et al. COVID-19 and tuberculosis: the double whammy of respiratory pathogens. Eur Respir Rev 2022; 31: 210264
    CrossrefPubMedGoogle Scholar
  • 46 Walitt B, Johnson TP. The pathogenesis of neurologic symptoms of the postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. Curr Opin Neurol 2022; 35: 384-391
    CrossrefPubMedGoogle Scholar
  • 47 Al-Kuraishy HM, Al-Gareeb AI, El-Bouseary MM. et al. Hyperviscosity syndrome in COVID-19 and related vaccines: exploring of uncertainties. Clin Exp Med 2022; 1-10
    PubMedGoogle Scholar
  • 48 Preiser JC. Oxidative stress. JPEN J Parenter Enteral Nutr 2012; 36: 147-154
    CrossrefPubMedGoogle Scholar
  • 49 Carr AC, Maggini S. Vitamin C and immune function. Nutrients 2017; 9: 1211
    CrossrefPubMedGoogle Scholar
  • 50 Jensen IJ, McGonagill PW, Berton RR. et al. Prolonged reactive oxygen species production following septic insult. Immunohorizons 2021; 5: 477-488
    CrossrefPubMedGoogle Scholar
  • 51 Vollbracht C, Kraft K. Feasibility of vitamin C in the treatment of post viral fatigue with focus on long COVID, based on a systematic review of IV vitamin C on fatigue. Nutrients 2021; 13: 1154
    CrossrefPubMedGoogle Scholar
  • 52 Pierce JD, Shen Q, Cintron SA. et al. Post-COVID-19 syndrome. Nurs Res 2022; 71: 164-174
    CrossrefPubMedGoogle Scholar
  • 53 Crook H, Raza S, Nowell J. et al. Long covid-mechanisms, risk factors, and management. BMJ 2021; 374: n1648
    CrossrefPubMedGoogle Scholar
  • 54 Matta J, Wiernik E, Robineau O. et al. Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among French adults during the COVID-19 pandemic. JAMA Intern Med 2022; 182: 19-25
    CrossrefPubMedGoogle Scholar
  • 55 Yang C, Zhao H, Tebbutt SJ. A glimpse into long COVID and symptoms. Lancet Respir Med 2022; 10: e81
    CrossrefPubMedGoogle Scholar
  • 56 Julius U. History of lipidology and lipoprotein apheresis. Atheroscler Suppl 2017; 30: 1-8
    CrossrefPubMedGoogle Scholar
  • 57 Julius U, Parhofer KG, Heibges A. et al. Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis-comparison of performance characteristics with DALI and lipidfiltration. J Clin Apher 2007; 22: 215-223
    CrossrefPubMedGoogle Scholar
  • 58 Straube R, Muller G, Voit-Bak K. et al. Metabolic and non-metabolic peripheral neuropathy: is there a place for therapeutic apheresis?. Horm Metab Res 2019; 51: 779-784
    Article in Thieme ConnectPubMedGoogle Scholar
  • 59 Zanetti M, Zenti M, Barazzoni R. et al. HELP LDL apheresis reduces plasma pentraxin 3 in familial hypercholesterolemia. PLoS One 2014; 9: e101290
    CrossrefPubMedGoogle Scholar
  • 60 Kopprasch S, Bornstein SR, Schwarz PE. et al. Single whole blood dextran sulfate adsorption favorably affects systemic oxidative balance in lipoprotein apheresis patients. Atheroscler Suppl 2013; 14: 157-160
    CrossrefPubMedGoogle Scholar
  • 61 Kopprasch S, Graessler J, Bornstein SR. Beyond lowering circulating LDL: apheresis-induced changes of systemic oxidative stress markers by four different techniques. Atheroscler Suppl 2009; 10: 34-38
    CrossrefPubMedGoogle Scholar
  • 62 Grassler J, Kopprasch S, Passauer J. Differential effects of lipoprotein apheresis by lipidfiltration or dextran sulfate adsorption on lipidomic profile. Atheroscler Suppl 2013; 14: 151-155
    CrossrefPubMedGoogle Scholar
  • 63 Julius U, Siegert G, Kostka H. et al. Effects of different lipoprotein apheresis methods on serum protein levels. Atheroscler Suppl 2015; 18: 95-102
    CrossrefPubMedGoogle Scholar
  • 64 Yin X, Takov K, Straube R. et al. Precision medicine approach for cardiometabolic risk factors in therapeutic apheresis. Horm Metab Res 2022; 54: 238-249
    Article in Thieme ConnectPubMedGoogle Scholar
  • 65 Hohenstein B, Passauer J, Ziemssen T. et al. Immunoadsorption with regenerating systems in neurological disorders – A single center experience. Atheroscler Suppl 2015; 18: 119-123
    CrossrefPubMedGoogle Scholar